

William Chu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6848751/publications.pdf>

Version: 2024-02-01

63
papers

1,370
citations

394390

19
h-index

361001

35
g-index

65
all docs

65
docs citations

65
times ranked

1560
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study. <i>Neuroendocrinology</i> , 2022, 112, 153-160.	2.5	10
2	Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 735-743.	0.8	4
3	Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?. <i>Radiotherapy and Oncology</i> , 2022, 169, 51-56.	0.6	8
4	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS398-TPS398.	1.6	3
5	Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). <i>Clinical Genitourinary Cancer</i> , 2022, 20, e353-e361.	1.9	3
6	Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. <i>Radiotherapy and Oncology</i> , 2021, 154, 29-35.	0.6	15
7	Salvage surgery for locally recurrent anal cancer after intensity modulated radiation therapy with concurrent chemotherapy. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100287.	1.7	2
8	Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial. <i>Radiotherapy and Oncology</i> , 2021, 156, 160-165.	0.6	12
9	Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 634830.	2.8	10
10	Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life. <i>Radiotherapy and Oncology</i> , 2021, 161, 40-46.	0.6	6
11	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters. <i>Radiotherapy and Oncology</i> , 2021, 161, 159-165.	0.6	14
12	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700.	1.9	65
13	Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials. <i>Radiotherapy and Oncology</i> , 2021, 163, 159-164.	0.6	8
14	Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 21-31.	0.6	7
15	2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium: Meeting highlights. <i>Canadian Urological Association Journal</i> , 2021, 16, 125-131.	0.6	0
16	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. <i>Radiotherapy and Oncology</i> , 2020, 142, 236-245.	0.6	27
17	Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 144, 135-140.	0.6	13
18	Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 941-949.	0.8	48

#	ARTICLE	IF	CITATIONS
19	Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19ÂGy or two fractions of 13.5ÂGy. <i>Radiotherapy and Oncology</i> , 2020, 146, 90-96.	0.6	92
20	Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 136-142.	0.8	21
21	Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29Âdays overall treatment time (PATRIOT). <i>Radiotherapy and Oncology</i> , 2020, 149, 8-13.	0.6	19
22	A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5065-5065.	1.6	7
23	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS761-TPS761.	1.6	12
24	Stereotactic radiotherapy +/- HDR boost for unfavorable-risk prostate cancer: Comparison of efficacy, survival, and late toxicity outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 372-372.	1.6	1
25	Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms. <i>Journal of Radiosurgery and SBRT</i> , 2020, 6, 321-324.	0.2	1
26	Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1066-1073.	0.8	9
27	Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. <i>Radiotherapy and Oncology</i> , 2019, 140, 105-109.	0.6	12
28	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1531-1543.	10.7	362
29	Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2019, 135, 86-90.	0.6	32
30	SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 36-41.	0.8	34
31	PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1-1.	1.6	18
32	SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3-3.	1.6	0
33	Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) hyperthermia for primary rectal cancer: A virtual feasibility analysis.. <i>Journal of Global Oncology</i> , 2019, 5, 77-77.	0.5	0
34	Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. <i>Radiotherapy and Oncology</i> , 2018, 127, 304-309.	0.6	49
35	Impact of Magnetic Resonance Imaging on Gross Tumor Volume Delineation in Non-spine Bony Metastasis Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 735-743.e1.	0.8	21
36	Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. <i>Radiotherapy and Oncology</i> , 2018, 127, 206-212.	0.6	54

#	ARTICLE	IF	CITATIONS
37	Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study). <i>Journal of Cancer Education</i> , 2018, 33, 551-556.	1.3	22
38	Phase III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 222-228.	0.6	34
39	Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1438-1447.	0.8	39
40	Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis. <i>Radiotherapy and Oncology</i> , 2018, 129, 435-440.	0.6	10
41	Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 5, 9-12.	2.9	7
42	Imaging predictors of treatment outcomes in rectal cancer: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 153-162.	4.4	17
43	Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?. <i>Lung Cancer</i> , 2018, 124, 219-226.	2.0	35
44	Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?. <i>Radiotherapy and Oncology</i> , 2017, 123, 478-482.	0.6	26
45	Magnetic Resonance-Guided High-Intensity-Focused Ultrasound for Palliation of Painful Skeletal Metastases: A Pilot Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 570-576.	1.9	20
46	Urinary cytokines/chemokines after magnetic resonance-guided high intensity focused ultrasound for palliative treatment of painful bone metastases. <i>Annals of Palliative Medicine</i> , 2017, 6, 36-54.	1.2	4
47	Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes.. <i>Journal of Clinical Oncology</i> , 2017, 35, 60-60.	1.6	2
48	Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive series. <i>Annals of Palliative Medicine</i> , 2016, 5, 116-124.	1.2	10
49	Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1043-1051.	0.8	33
50	Implementation of a volumetric modulated arc therapy treatment planning solution for kidney and adrenal stereotactic body radiation therapy. <i>Medical Dosimetry</i> , 2016, 41, 323-328.	0.9	4
51	Dosimetric comparison of volumetric modulated arc therapy and intensity-modulated radiation therapy for liver stereotactic ablative body radiotherapy. <i>Journal of Radiation Oncology</i> , 2016, 5, 63-69.	0.7	3
52	Computed Tomography Evaluation of Density Following Stereotactic Body Radiation Therapy of Nonspine Bone Metastases. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 683-688.	1.9	3
53	4DCT Simulation With Synchronized Contrast Injection in Liver SBRT Patients. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 55-59.	1.9	13
54	Phase I/II study of stereotactic ablative radiotherapy including regional lymph node irradiation for patients with high-risk prostate cancer (SATURN): Early results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 264-264.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Predictive parameters of symptomatic haematochezia following 5-fraction gantry-based SABR in prostate cancer.. Journal of Clinical Oncology, 2016, 34, 79-79.	1.6	0
56	Poster - 55: Active Breathing Coordinator Based Treatment of Liver SBRT Patients. Medical Physics, 2016, 43, 4950-4950.	3.0	0
57	Stereotactic body radiation therapy for non-spine bone metastases--a review of the literature. Annals of Palliative Medicine, 2016, 5, 58-66.	1.2	27
58	Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions. Canadian Urological Association Journal, 2015, 9, 275.	0.6	27
59	Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Radiation Oncology, 2015, 10, 95.	2.7	4
60	Tumor Response After Stereotactic Body Radiation Therapy to Nonspine Bone Metastases: An Evaluation of Response Criteria. International Journal of Radiation Oncology Biology Physics, 2015, 93, 879-881.	0.8	17
61	PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time.. Journal of Clinical Oncology, 2015, 33, 6-6.	1.6	9
62	Radiation therapy for primary and metastatic tumors of the liver. Journal of Radiation Oncology, 2012, 1, 227-237.	0.7	2
63	Comparison of acute toxicity in patients treated with a 4-field box or IMRT to deliver elective pelvic nodal irradiation for localized high-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 69-69.	1.6	0